{"classes":[{"categories":[{"measurements":[{"comment":"Median OS was not estimable as 14 of the 17 participants were censored by 25 May 2011","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit not reached","groupId":"OG001","lowerLimit":"3.2","upperLimit":"NA","value":"8.6"},{"groupId":"OG002","lowerLimit":"1.7","upperLimit":"4.4","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Defined as time in months from start of study therapy to death. The OS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median OS time was computed using the Brookmeyer and Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose Level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2, Escalated/Dose level 3 of 100 mg/m\\^2, and Escalated/Dose level 4 of 120 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose"}],"paramType":"MEDIAN","populationDescription":"All treated participants: Participants who received at least 1 dose of study therapy. Participants lost to followup were censored on the last date the participant was known to be alive.","reportingStatus":"POSTED","timeFrame":"From start of study therapy until death or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}